The clinical value of mNGS of bronchoalveolar lavage fluid versus traditional microbiological tests for pathogen identification and prognosis of severe pneumonia (NT-BALF):study protocol for a prospective multi-center randomized clinical trial

• Published in: Current controlled trials in cardiovascular medicine 2024-04, Vol.25 (1), p.276-276, Article 276
• Main Authors: Song, Xiao, Jiang, Hui, Zong, Liang, Shi, Di, Zhu, Huadong
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Anti-Bacterial Agents - therapeutic use; Bacterial pneumonia; Bronchoalveolar lavage; Bronchoalveolar lavage fluid; Bronchoalveolar Lavage Fluid - microbiology; Care and treatment; China; Cost-Benefit Analysis; Cost-effectiveness; Development and progression; Drug resistance; High-Throughput Nucleotide Sequencing; Humans; Laboratories; Length of Stay; Male; Medical prognosis; Metagenomics - methods; Microbiological Techniques - methods; Middle Aged; mNGS; Mortality; Multicenter Studies as Topic; Pneumonia; Pneumonia - diagnosis; Pneumonia - drug therapy; Pneumonia - microbiology; Pneumonia - mortality; Predictive Value of Tests; Prevention; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Severe pneumonia; Severity of Illness Index; Study Protocol; Time Factors; Traditional microbiological tests; Treatment Outcome; Ventilators
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-024-08112-x

Early, rapid, and accurate pathogen diagnosis can help clinicians select targeted treatment options, thus improving prognosis and reducing mortality rates of severe pneumonia. Metagenomic next-generation sequencing (mNGS) has a higher sensitivity and broader pathogen spectrum than traditional microbiological tests. However, the effects of mNGS-based antimicrobial treatment procedures on clinical outcomes and cost-effectiveness in patients with severe pneumonia have not been evaluated. This is a regional, multi-center, open, prospective, randomized controlled trial to evaluate that whether the combination of mNGS and traditional testing methods could decrease 28-day call-cause mortality with moderate cost-effectiveness. A total of 192 patients with severe pneumonia will be recruited from four large tertiary hospitals in China. Bronchoalveolar lavage fluid will be obtained in all patients and randomly assigned to the study group (mNGS combined with traditional microbiological tests) or the control group (traditional microbiological tests only) in a 1:1 ratio. Individualized antimicrobial treatment and strategy will be selected according to the analysis results. The primary outcome is 28-day all-cause mortality. The secondary outcomes are ICU and hospital length of stay (LOS), ventilator-free days and ICU-free days, consistency between mNGS and traditional microbiological tests, detective rate of mNGS and traditional microbiological tests, turn-out time, time from group allocation to start of treatment, duration of vasopressor support, types and duration of anti-infective regimens, source of drug-resistant bacteria or fungi, and ICU cost. The clinical benefits of mNGS are potentially significant, but its limitations should also be considered. ChineseClinicalTrialRegistry.org, ChiCTR2300076853. Registered on 22 October 2023.